# PeptideScanner evidence objects: Hexarelin

Every published version of the records placed with Hexarelin, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/hexarelin.json. Selected public evidence only; not medical advice.

- Objects: 24
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="pubmed-pmid-10469018-hexarelin-v1"></a>

## Hexarelin as a test of pituitary reserve in patients with pituitary disease.

> PubMed lists PMID 10469018 in Clinical endocrinology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1999-09 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-10469018-hexarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-08-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-10469018-hexarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-10469018-hexarelin-v1
- Content SHA-256: `7593c2aedc5ab93981396c9d591da0bcf5130bb450232171438a08f9c01cd17a`

### Claims and source pins

#### Headline

Hexarelin as a test of pituitary reserve in patients with pituitary disease. ([`pubmed-observation-pmid-10469018-2019-08-13-b68892b98d11`](#source-pubmed-observation-pmid-10469018-2019-08-13-b68892b98d11))

#### Summary

PubMed lists PMID 10469018 in Clinical endocrinology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1999-09 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-10469018-2019-08-13-b68892b98d11`](#source-pubmed-observation-pmid-10469018-2019-08-13-b68892b98d11))

#### Paragraph 1

PubMed lists PMID 10469018 in Clinical endocrinology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1999-09 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-10469018-2019-08-13-b68892b98d11`](#source-pubmed-observation-pmid-10469018-2019-08-13-b68892b98d11))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-10469018-2019-08-13-b68892b98d11`](#source-pubmed-observation-pmid-10469018-2019-08-13-b68892b98d11))

### Sources

<a id="source-pubmed-observation-pmid-10469018-2019-08-13-b68892b98d11"></a>
- **Hexarelin as a test of pituitary reserve in patients with pituitary disease. · retained source version 1:2019-08-13:current:b68892b98d11abd36bd26aae63d58687f19819a6da5be37136d0ea77220c717d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/10469018/) (`pubmed-observation-pmid-10469018-2019-08-13-b68892b98d11`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Hexarelin as a test of pituitary reserve in patients with pituitary disease." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-10469018-hexarelin-v1 SHA-256: 7593c2aedc5ab93981396c9d591da0bcf5130bb450232171438a08f9c01cd17a.

---

<a id="pubmed-pmid-10512687-hexarelin-v1"></a>

## Hexarelin, a growth hormone - releasing peptide, counteracts bone loss in gonadectomized male rats.

> PubMed lists PMID 10512687 in Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1999-08 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-10512687-hexarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2012-11-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-10512687-hexarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-10512687-hexarelin-v1
- Content SHA-256: `364268f0843f57f6f8a2353e100399a4a2f21434f69ab782f399d19d41646f45`

### Claims and source pins

#### Headline

Hexarelin, a growth hormone - releasing peptide, counteracts bone loss in gonadectomized male rats. ([`pubmed-observation-pmid-10512687-2012-11-15-249e824944c4`](#source-pubmed-observation-pmid-10512687-2012-11-15-249e824944c4))

#### Summary

PubMed lists PMID 10512687 in Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1999-08 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-10512687-2012-11-15-249e824944c4`](#source-pubmed-observation-pmid-10512687-2012-11-15-249e824944c4))

#### Paragraph 1

PubMed lists PMID 10512687 in Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1999-08 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-10512687-2012-11-15-249e824944c4`](#source-pubmed-observation-pmid-10512687-2012-11-15-249e824944c4))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-10512687-2012-11-15-249e824944c4`](#source-pubmed-observation-pmid-10512687-2012-11-15-249e824944c4))

### Sources

<a id="source-pubmed-observation-pmid-10512687-2012-11-15-249e824944c4"></a>
- **Hexarelin, a growth hormone - releasing peptide, counteracts bone loss in gonadectomized male rats. · retained source version 1:2012-11-15:current:249e824944c452c0c6f511c07617502ea181902f01fc4f1d54230294b66f1373** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/10512687/) (`pubmed-observation-pmid-10512687-2012-11-15-249e824944c4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Hexarelin, a growth hormone - releasing peptide, counteracts bone loss in gonadectomized male rats." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-10512687-hexarelin-v1 SHA-256: 364268f0843f57f6f8a2353e100399a4a2f21434f69ab782f399d19d41646f45.

---

<a id="pubmed-pmid-10611139-hexarelin-v1"></a>

## Kinetics and disposition of hexarelin, a peptidic growth hormone secretagogue, in rats.

> PubMed lists PMID 10611139 in Drug metabolism and disposition: the biological fate of chemicals as Journal Article, with publication-date metadata of 2000-01 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-10611139-hexarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2012-11-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-10611139-hexarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-10611139-hexarelin-v1
- Content SHA-256: `09e00af4e002ad6b1817ac5c3bb0129693ea4720d86a10e6716c7794f6f92460`

### Claims and source pins

#### Headline

Kinetics and disposition of hexarelin, a peptidic growth hormone secretagogue, in rats. ([`pubmed-observation-pmid-10611139-2012-11-15-1376ca73b8eb`](#source-pubmed-observation-pmid-10611139-2012-11-15-1376ca73b8eb))

#### Summary

PubMed lists PMID 10611139 in Drug metabolism and disposition: the biological fate of chemicals as Journal Article, with publication-date metadata of 2000-01 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-10611139-2012-11-15-1376ca73b8eb`](#source-pubmed-observation-pmid-10611139-2012-11-15-1376ca73b8eb))

#### Paragraph 1

PubMed lists PMID 10611139 in Drug metabolism and disposition: the biological fate of chemicals as Journal Article, with publication-date metadata of 2000-01 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-10611139-2012-11-15-1376ca73b8eb`](#source-pubmed-observation-pmid-10611139-2012-11-15-1376ca73b8eb))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-10611139-2012-11-15-1376ca73b8eb`](#source-pubmed-observation-pmid-10611139-2012-11-15-1376ca73b8eb))

### Sources

<a id="source-pubmed-observation-pmid-10611139-2012-11-15-1376ca73b8eb"></a>
- **Kinetics and disposition of hexarelin, a peptidic growth hormone secretagogue, in rats. · retained source version 1:2012-11-15:current:1376ca73b8ebb4b63c84039f349c0cb495ac91fadcb549d897c3a78e06701cb8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/10611139/) (`pubmed-observation-pmid-10611139-2012-11-15-1376ca73b8eb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Kinetics and disposition of hexarelin, a peptidic growth hormone secretagogue, in rats." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-10611139-hexarelin-v1 SHA-256: 09e00af4e002ad6b1817ac5c3bb0129693ea4720d86a10e6716c7794f6f92460.

---

<a id="pubmed-pmid-10727060-hexarelin-v1"></a>

## Corticotroph and adrenal responsiveness to hCRH, hexarelin and ACTH in young and elderly subjects.

> PubMed lists PMID 10727060 in Journal of endocrinological investigation as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1999 (year precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-10727060-hexarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-11-30
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-10727060-hexarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-10727060-hexarelin-v1
- Content SHA-256: `c1f9f259a19aef84af56176c1e54e43075cb0625ac70f0b55e7f280b7026d205`

### Claims and source pins

#### Headline

Corticotroph and adrenal responsiveness to hCRH, hexarelin and ACTH in young and elderly subjects. ([`pubmed-observation-pmid-10727060-2018-11-30-413639a0b6fb`](#source-pubmed-observation-pmid-10727060-2018-11-30-413639a0b6fb))

#### Summary

PubMed lists PMID 10727060 in Journal of endocrinological investigation as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1999 (year precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-10727060-2018-11-30-413639a0b6fb`](#source-pubmed-observation-pmid-10727060-2018-11-30-413639a0b6fb))

#### Paragraph 1

PubMed lists PMID 10727060 in Journal of endocrinological investigation as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1999 (year precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-10727060-2018-11-30-413639a0b6fb`](#source-pubmed-observation-pmid-10727060-2018-11-30-413639a0b6fb))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-10727060-2018-11-30-413639a0b6fb`](#source-pubmed-observation-pmid-10727060-2018-11-30-413639a0b6fb))

### Sources

<a id="source-pubmed-observation-pmid-10727060-2018-11-30-413639a0b6fb"></a>
- **Corticotroph and adrenal responsiveness to hCRH, hexarelin and ACTH in young and elderly subjects. · retained source version 1:2018-11-30:current:413639a0b6fb98f6d69ec2201100672dbf5163b498066f9dd5bcfd8dc3693de3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/10727060/) (`pubmed-observation-pmid-10727060-2018-11-30-413639a0b6fb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Corticotroph and adrenal responsiveness to hCRH, hexarelin and ACTH in young and elderly subjects." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-10727060-hexarelin-v1 SHA-256: c1f9f259a19aef84af56176c1e54e43075cb0625ac70f0b55e7f280b7026d205.

---

<a id="pubmed-pmid-10990150-hexarelin-v1"></a>

## Does desensitization to hexarelin occur?

> PubMed lists PMID 10990150 in Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society as Clinical Trial, Journal Article, with publication-date metadata of 1998-04 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-10990150-hexarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-11-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-10990150-hexarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-10990150-hexarelin-v1
- Content SHA-256: `e5f342d6896d4787d29cf865699605e35cdbdb140bc089b56b49690aa58f2290`

### Claims and source pins

#### Headline

Does desensitization to hexarelin occur? ([`pubmed-observation-pmid-10990150-2019-11-04-3e27d132cd53`](#source-pubmed-observation-pmid-10990150-2019-11-04-3e27d132cd53))

#### Summary

PubMed lists PMID 10990150 in Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society as Clinical Trial, Journal Article, with publication-date metadata of 1998-04 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-10990150-2019-11-04-3e27d132cd53`](#source-pubmed-observation-pmid-10990150-2019-11-04-3e27d132cd53))

#### Paragraph 1

PubMed lists PMID 10990150 in Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society as Clinical Trial, Journal Article, with publication-date metadata of 1998-04 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-10990150-2019-11-04-3e27d132cd53`](#source-pubmed-observation-pmid-10990150-2019-11-04-3e27d132cd53))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-10990150-2019-11-04-3e27d132cd53`](#source-pubmed-observation-pmid-10990150-2019-11-04-3e27d132cd53))

### Sources

<a id="source-pubmed-observation-pmid-10990150-2019-11-04-3e27d132cd53"></a>
- **Does desensitization to hexarelin occur? · retained source version 1:2019-11-04:current:3e27d132cd53d02bf867bc3dde80e052ba386fe0b3f0844518105990dde75a2e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/10990150/) (`pubmed-observation-pmid-10990150-2019-11-04-3e27d132cd53`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Does desensitization to hexarelin occur?" Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-10990150-hexarelin-v1 SHA-256: e5f342d6896d4787d29cf865699605e35cdbdb140bc089b56b49690aa58f2290.

---

<a id="pubmed-pmid-11238504-hexarelin-v1"></a>

## Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.

> PubMed lists PMID 11238504 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2001-03 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-11238504-hexarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-03-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-11238504-hexarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-11238504-hexarelin-v1
- Content SHA-256: `b622797cea223dc12925acfed0bfc0947b05e6acd1d6d053e93907cb80c2104d`

### Claims and source pins

#### Headline

Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. ([`pubmed-observation-pmid-11238504-2022-03-09-118804b5464b`](#source-pubmed-observation-pmid-11238504-2022-03-09-118804b5464b))

#### Summary

PubMed lists PMID 11238504 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2001-03 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-11238504-2022-03-09-118804b5464b`](#source-pubmed-observation-pmid-11238504-2022-03-09-118804b5464b))

#### Paragraph 1

PubMed lists PMID 11238504 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2001-03 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-11238504-2022-03-09-118804b5464b`](#source-pubmed-observation-pmid-11238504-2022-03-09-118804b5464b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-11238504-2022-03-09-118804b5464b`](#source-pubmed-observation-pmid-11238504-2022-03-09-118804b5464b))

### Sources

<a id="source-pubmed-observation-pmid-11238504-2022-03-09-118804b5464b"></a>
- **Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. · retained source version 1:2022-03-09:current:118804b5464b6e2db2763f48b067d3564992e84b7b6e331cc80cba757d981714** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/11238504/) (`pubmed-observation-pmid-11238504-2022-03-09-118804b5464b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-11238504-hexarelin-v1 SHA-256: b622797cea223dc12925acfed0bfc0947b05e6acd1d6d053e93907cb80c2104d.

---

<a id="pubmed-pmid-11445244-hexarelin-v1"></a>

## Permeability of the peptidic GH secretagogues hexarelin and EP 51389, across rat jejunum.

> PubMed lists PMID 11445244 in Peptides as Journal Article, with publication-date metadata of 2001-07 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-11445244-hexarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-08-18
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-11445244-hexarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-11445244-hexarelin-v1
- Content SHA-256: `f024533c45a58b87e8afd8ca80bdf5aea7fc68294f49ee8555c68892a5fa21b0`

### Claims and source pins

#### Headline

Permeability of the peptidic GH secretagogues hexarelin and EP 51389, across rat jejunum. ([`pubmed-observation-pmid-11445244-2019-08-18-92d3c8041a3e`](#source-pubmed-observation-pmid-11445244-2019-08-18-92d3c8041a3e))

#### Summary

PubMed lists PMID 11445244 in Peptides as Journal Article, with publication-date metadata of 2001-07 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-11445244-2019-08-18-92d3c8041a3e`](#source-pubmed-observation-pmid-11445244-2019-08-18-92d3c8041a3e))

#### Paragraph 1

PubMed lists PMID 11445244 in Peptides as Journal Article, with publication-date metadata of 2001-07 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-11445244-2019-08-18-92d3c8041a3e`](#source-pubmed-observation-pmid-11445244-2019-08-18-92d3c8041a3e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-11445244-2019-08-18-92d3c8041a3e`](#source-pubmed-observation-pmid-11445244-2019-08-18-92d3c8041a3e))

### Sources

<a id="source-pubmed-observation-pmid-11445244-2019-08-18-92d3c8041a3e"></a>
- **Permeability of the peptidic GH secretagogues hexarelin and EP 51389, across rat jejunum. · retained source version 1:2019-08-18:current:92d3c8041a3ed0f25aa02b02eaff0d7db8e6240a2e6af99e0ed25a18a26354ef** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/11445244/) (`pubmed-observation-pmid-11445244-2019-08-18-92d3c8041a3e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Permeability of the peptidic GH secretagogues hexarelin and EP 51389, across rat jejunum." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-11445244-hexarelin-v1 SHA-256: f024533c45a58b87e8afd8ca80bdf5aea7fc68294f49ee8555c68892a5fa21b0.

---

<a id="pubmed-pmid-11959048-hexarelin-v1"></a>

## GH-independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy.

> PubMed lists PMID 11959048 in European journal of heart failure as Comparative Study, Evaluation Study, Journal Article, with publication-date metadata of 2002-03 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-11959048-hexarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-12-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-11959048-hexarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-11959048-hexarelin-v1
- Content SHA-256: `6c8cb8a70ee230d6788c8ede5bf54149d62c08f969ba291478d4582686d0cc0d`

### Claims and source pins

#### Headline

GH-independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy. ([`pubmed-observation-pmid-11959048-2019-12-10-f6939c668a24`](#source-pubmed-observation-pmid-11959048-2019-12-10-f6939c668a24))

#### Summary

PubMed lists PMID 11959048 in European journal of heart failure as Comparative Study, Evaluation Study, Journal Article, with publication-date metadata of 2002-03 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-11959048-2019-12-10-f6939c668a24`](#source-pubmed-observation-pmid-11959048-2019-12-10-f6939c668a24))

#### Paragraph 1

PubMed lists PMID 11959048 in European journal of heart failure as Comparative Study, Evaluation Study, Journal Article, with publication-date metadata of 2002-03 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-11959048-2019-12-10-f6939c668a24`](#source-pubmed-observation-pmid-11959048-2019-12-10-f6939c668a24))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-11959048-2019-12-10-f6939c668a24`](#source-pubmed-observation-pmid-11959048-2019-12-10-f6939c668a24))

### Sources

<a id="source-pubmed-observation-pmid-11959048-2019-12-10-f6939c668a24"></a>
- **GH-independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy. · retained source version 1:2019-12-10:current:f6939c668a24d1a927ddd1f7859235de431ae953f5e4dd6cf2fce4a494633241** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/11959048/) (`pubmed-observation-pmid-11959048-2019-12-10-f6939c668a24`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "GH-independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-11959048-hexarelin-v1 SHA-256: 6c8cb8a70ee230d6788c8ede5bf54149d62c08f969ba291478d4582686d0cc0d.

---

<a id="pubmed-pmid-14669829-hexarelin-v1"></a>

## Rapid desensitisation of the GH secretagogue (ghrelin) receptor to hexarelin in vitro.

> PubMed lists PMID 14669829 in Journal of endocrinological investigation as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2003-08 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-14669829-hexarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-11-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-14669829-hexarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-14669829-hexarelin-v1
- Content SHA-256: `9195499a9b3b0b43723fc1c1b42596a532af641dd6ea1c7c6a4e9e9031815b6d`

### Claims and source pins

#### Headline

Rapid desensitisation of the GH secretagogue (ghrelin) receptor to hexarelin in vitro. ([`pubmed-observation-pmid-14669829-2018-11-13-a4161af40a15`](#source-pubmed-observation-pmid-14669829-2018-11-13-a4161af40a15))

#### Summary

PubMed lists PMID 14669829 in Journal of endocrinological investigation as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2003-08 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-14669829-2018-11-13-a4161af40a15`](#source-pubmed-observation-pmid-14669829-2018-11-13-a4161af40a15))

#### Paragraph 1

PubMed lists PMID 14669829 in Journal of endocrinological investigation as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2003-08 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-14669829-2018-11-13-a4161af40a15`](#source-pubmed-observation-pmid-14669829-2018-11-13-a4161af40a15))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-14669829-2018-11-13-a4161af40a15`](#source-pubmed-observation-pmid-14669829-2018-11-13-a4161af40a15))

### Sources

<a id="source-pubmed-observation-pmid-14669829-2018-11-13-a4161af40a15"></a>
- **Rapid desensitisation of the GH secretagogue (ghrelin) receptor to hexarelin in vitro. · retained source version 1:2018-11-13:current:a4161af40a15aae37d13e52ffe72ff9cd46bde719b577964a902d13fe0bb642f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/14669829/) (`pubmed-observation-pmid-14669829-2018-11-13-a4161af40a15`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Rapid desensitisation of the GH secretagogue (ghrelin) receptor to hexarelin in vitro." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-14669829-hexarelin-v1 SHA-256: 9195499a9b3b0b43723fc1c1b42596a532af641dd6ea1c7c6a4e9e9031815b6d.

---

<a id="pubmed-pmid-18288286-hexarelin-v1"></a>

## Hexarelin Signaling to PPARgamma in Metabolic Diseases.

> PubMed lists PMID 18288286 in PPAR research as Journal Article, with publication-date metadata of 2008 (year precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-18288286-hexarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-10-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18288286-hexarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-18288286-hexarelin-v1
- Content SHA-256: `e2fcdab536e498784a2acbc61368f8cf82fa5303628fa88092aef9fc3897e78f`

### Claims and source pins

#### Headline

Hexarelin Signaling to PPARgamma in Metabolic Diseases. ([`pubmed-observation-pmid-18288286-2021-10-20-706c46ecd71e`](#source-pubmed-observation-pmid-18288286-2021-10-20-706c46ecd71e))

#### Summary

PubMed lists PMID 18288286 in PPAR research as Journal Article, with publication-date metadata of 2008 (year precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18288286-2021-10-20-706c46ecd71e`](#source-pubmed-observation-pmid-18288286-2021-10-20-706c46ecd71e))

#### Paragraph 1

PubMed lists PMID 18288286 in PPAR research as Journal Article, with publication-date metadata of 2008 (year precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18288286-2021-10-20-706c46ecd71e`](#source-pubmed-observation-pmid-18288286-2021-10-20-706c46ecd71e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18288286-2021-10-20-706c46ecd71e`](#source-pubmed-observation-pmid-18288286-2021-10-20-706c46ecd71e))

### Sources

<a id="source-pubmed-observation-pmid-18288286-2021-10-20-706c46ecd71e"></a>
- **Hexarelin Signaling to PPARgamma in Metabolic Diseases. · retained source version 1:2021-10-20:current:706c46ecd71e03e44c09ff1135dfcb4b993dc7a9558915ec01ce5b7e4d9abb95** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18288286/) (`pubmed-observation-pmid-18288286-2021-10-20-706c46ecd71e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Hexarelin Signaling to PPARgamma in Metabolic Diseases." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-18288286-hexarelin-v1 SHA-256: e2fcdab536e498784a2acbc61368f8cf82fa5303628fa88092aef9fc3897e78f.

---

<a id="pubmed-pmid-18787392-hexarelin-v1"></a>

## Hexarelin: a multi-receptor peptide.

> PubMed lists PMID 18787392 in Journal of endocrinological investigation as Letter, with publication-date metadata of 2008-07 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-18787392-hexarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-10-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18787392-hexarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-18787392-hexarelin-v1
- Content SHA-256: `f398a40bf79852e3ae7cce7ab7d194111fc9ca9014576161eb0589d2579bb376`

### Claims and source pins

#### Headline

Hexarelin: a multi-receptor peptide. ([`pubmed-observation-pmid-18787392-2021-10-20-3a3ef03742c9`](#source-pubmed-observation-pmid-18787392-2021-10-20-3a3ef03742c9))

#### Summary

PubMed lists PMID 18787392 in Journal of endocrinological investigation as Letter, with publication-date metadata of 2008-07 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18787392-2021-10-20-3a3ef03742c9`](#source-pubmed-observation-pmid-18787392-2021-10-20-3a3ef03742c9))

#### Paragraph 1

PubMed lists PMID 18787392 in Journal of endocrinological investigation as Letter, with publication-date metadata of 2008-07 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18787392-2021-10-20-3a3ef03742c9`](#source-pubmed-observation-pmid-18787392-2021-10-20-3a3ef03742c9))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18787392-2021-10-20-3a3ef03742c9`](#source-pubmed-observation-pmid-18787392-2021-10-20-3a3ef03742c9))

### Sources

<a id="source-pubmed-observation-pmid-18787392-2021-10-20-3a3ef03742c9"></a>
- **Hexarelin: a multi-receptor peptide. · retained source version 1:2021-10-20:current:3a3ef03742c95ed4bcb15091fdc4a4df663bf405b270aef3180c71334faefbaa** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18787392/) (`pubmed-observation-pmid-18787392-2021-10-20-3a3ef03742c9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Hexarelin: a multi-receptor peptide." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-18787392-hexarelin-v1 SHA-256: f398a40bf79852e3ae7cce7ab7d194111fc9ca9014576161eb0589d2579bb376.

---

<a id="pubmed-pmid-22401277-hexarelin-v1"></a>

## Reproductive performance and fertility in male and female adult mice chronically treated with hexarelin.

> PubMed lists PMID 22401277 in Reproduction, fertility, and development as Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012 (year precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-22401277-hexarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-12-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22401277-hexarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-22401277-hexarelin-v1
- Content SHA-256: `e984acc8487c009fb1018d762f102eeaa0be50b018e7f63716b48573a54067f1`

### Claims and source pins

#### Headline

Reproductive performance and fertility in male and female adult mice chronically treated with hexarelin. ([`pubmed-observation-pmid-22401277-2019-12-10-3fc9a468855d`](#source-pubmed-observation-pmid-22401277-2019-12-10-3fc9a468855d))

#### Summary

PubMed lists PMID 22401277 in Reproduction, fertility, and development as Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012 (year precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22401277-2019-12-10-3fc9a468855d`](#source-pubmed-observation-pmid-22401277-2019-12-10-3fc9a468855d))

#### Paragraph 1

PubMed lists PMID 22401277 in Reproduction, fertility, and development as Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012 (year precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22401277-2019-12-10-3fc9a468855d`](#source-pubmed-observation-pmid-22401277-2019-12-10-3fc9a468855d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22401277-2019-12-10-3fc9a468855d`](#source-pubmed-observation-pmid-22401277-2019-12-10-3fc9a468855d))

### Sources

<a id="source-pubmed-observation-pmid-22401277-2019-12-10-3fc9a468855d"></a>
- **Reproductive performance and fertility in male and female adult mice chronically treated with hexarelin. · retained source version 1:2019-12-10:current:3fc9a468855dc148ce9cb38d6c05c33f983b97b78d8947499a2474902fa4399f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22401277/) (`pubmed-observation-pmid-22401277-2019-12-10-3fc9a468855d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Reproductive performance and fertility in male and female adult mice chronically treated with hexarelin." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-22401277-hexarelin-v1 SHA-256: e984acc8487c009fb1018d762f102eeaa0be50b018e7f63716b48573a54067f1.

---

<a id="pubmed-pmid-23861368-hexarelin-v1"></a>

## Hexarelin treatment in male ghrelin knockout mice after myocardial infarction.

> PubMed lists PMID 23861368 in Endocrinology as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-07-16 (day precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23861368-hexarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-25
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23861368-hexarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-23861368-hexarelin-v1
- Content SHA-256: `ed558b513a619b77346fc381c52d936d78bd0c9ca1550e61c300a9e5e3d8a3e3`

### Claims and source pins

#### Headline

Hexarelin treatment in male ghrelin knockout mice after myocardial infarction. ([`pubmed-observation-pmid-23861368-2016-11-25-6d16b079a37e`](#source-pubmed-observation-pmid-23861368-2016-11-25-6d16b079a37e))

#### Summary

PubMed lists PMID 23861368 in Endocrinology as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-07-16 (day precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23861368-2016-11-25-6d16b079a37e`](#source-pubmed-observation-pmid-23861368-2016-11-25-6d16b079a37e))

#### Paragraph 1

PubMed lists PMID 23861368 in Endocrinology as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-07-16 (day precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23861368-2016-11-25-6d16b079a37e`](#source-pubmed-observation-pmid-23861368-2016-11-25-6d16b079a37e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23861368-2016-11-25-6d16b079a37e`](#source-pubmed-observation-pmid-23861368-2016-11-25-6d16b079a37e))

### Sources

<a id="source-pubmed-observation-pmid-23861368-2016-11-25-6d16b079a37e"></a>
- **Hexarelin treatment in male ghrelin knockout mice after myocardial infarction. · retained source version 1:2016-11-25:current:6d16b079a37eda0f05e75bfa273db1fb3b1223048baa78c98c5257aa07bbeae9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23861368/) (`pubmed-observation-pmid-23861368-2016-11-25-6d16b079a37e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Hexarelin treatment in male ghrelin knockout mice after myocardial infarction." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-23861368-hexarelin-v1 SHA-256: ed558b513a619b77346fc381c52d936d78bd0c9ca1550e61c300a9e5e3d8a3e3.

---

<a id="pubmed-pmid-32403043-hexarelin-v1"></a>

## Hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in a mouse model of myocardial ischemia-reperfusion.

> PubMed lists PMID 32403043 in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie as Journal Article, with publication-date metadata of 2020-05-08 (day precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32403043-hexarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-02-11
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32403043-hexarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-32403043-hexarelin-v1
- Content SHA-256: `2c229d6bb3452f717a2332cb89cf810b32c55dbafc438f3116c70aa060fd79d0`

### Claims and source pins

#### Headline

Hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in a mouse model of myocardial ischemia-reperfusion. ([`pubmed-observation-pmid-32403043-2021-02-11-958fd17f3ef7`](#source-pubmed-observation-pmid-32403043-2021-02-11-958fd17f3ef7))

#### Summary

PubMed lists PMID 32403043 in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie as Journal Article, with publication-date metadata of 2020-05-08 (day precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32403043-2021-02-11-958fd17f3ef7`](#source-pubmed-observation-pmid-32403043-2021-02-11-958fd17f3ef7))

#### Paragraph 1

PubMed lists PMID 32403043 in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie as Journal Article, with publication-date metadata of 2020-05-08 (day precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32403043-2021-02-11-958fd17f3ef7`](#source-pubmed-observation-pmid-32403043-2021-02-11-958fd17f3ef7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32403043-2021-02-11-958fd17f3ef7`](#source-pubmed-observation-pmid-32403043-2021-02-11-958fd17f3ef7))

### Sources

<a id="source-pubmed-observation-pmid-32403043-2021-02-11-958fd17f3ef7"></a>
- **Hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in a mouse model of myocardial ischemia-reperfusion. · retained source version 1:2021-02-11:current:958fd17f3ef7a475cf9b21777ece2a8d550f8015bcca853c30162b6cf5e6ee87** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32403043/) (`pubmed-observation-pmid-32403043-2021-02-11-958fd17f3ef7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in a mouse model of myocardial ischemia-reperfusion." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-32403043-hexarelin-v1 SHA-256: 2c229d6bb3452f717a2332cb89cf810b32c55dbafc438f3116c70aa060fd79d0.

---

<a id="pubmed-pmid-9231048-hexarelin-v1"></a>

## Absence of desensitization by hexarelin to subsequent GH releasing hormone-mediated GH secretion in patients with anorexia nervosa.

> PubMed lists PMID 9231048 in Clinical endocrinology as Journal Article, with publication-date metadata of 1997-05 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-9231048-hexarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-08-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-9231048-hexarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-9231048-hexarelin-v1
- Content SHA-256: `969410e44d66a110eb2cebf881195f37934c5300c5fdcdc9cc21b0e2d8bfd4a3`

### Claims and source pins

#### Headline

Absence of desensitization by hexarelin to subsequent GH releasing hormone-mediated GH secretion in patients with anorexia nervosa. ([`pubmed-observation-pmid-9231048-2019-08-13-1c8d1fe5f16f`](#source-pubmed-observation-pmid-9231048-2019-08-13-1c8d1fe5f16f))

#### Summary

PubMed lists PMID 9231048 in Clinical endocrinology as Journal Article, with publication-date metadata of 1997-05 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9231048-2019-08-13-1c8d1fe5f16f`](#source-pubmed-observation-pmid-9231048-2019-08-13-1c8d1fe5f16f))

#### Paragraph 1

PubMed lists PMID 9231048 in Clinical endocrinology as Journal Article, with publication-date metadata of 1997-05 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9231048-2019-08-13-1c8d1fe5f16f`](#source-pubmed-observation-pmid-9231048-2019-08-13-1c8d1fe5f16f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-9231048-2019-08-13-1c8d1fe5f16f`](#source-pubmed-observation-pmid-9231048-2019-08-13-1c8d1fe5f16f))

### Sources

<a id="source-pubmed-observation-pmid-9231048-2019-08-13-1c8d1fe5f16f"></a>
- **Absence of desensitization by hexarelin to subsequent GH releasing hormone-mediated GH secretion in patients with anorexia nervosa. · retained source version 1:2019-08-13:current:1c8d1fe5f16fc74e7fc186215bdaa319d71306fbbe872b08fdaa295b00cdd863** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/9231048/) (`pubmed-observation-pmid-9231048-2019-08-13-1c8d1fe5f16f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Absence of desensitization by hexarelin to subsequent GH releasing hormone-mediated GH secretion in patients with anorexia nervosa." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-9231048-hexarelin-v1 SHA-256: 969410e44d66a110eb2cebf881195f37934c5300c5fdcdc9cc21b0e2d8bfd4a3.

---

<a id="pubmed-pmid-9258804-hexarelin-v1"></a>

## Hexarelin is a stronger GH-releasing peptide than GHRH in normal cycling women but not in anorexia nervosa.

> PubMed lists PMID 9258804 in Journal of endocrinological investigation as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1997-05 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-9258804-hexarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-12
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-9258804-hexarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-9258804-hexarelin-v1
- Content SHA-256: `3d7207227bef3a120288543cf808c696132ee37d0c23167b18752d4c1d568df8`

### Claims and source pins

#### Headline

Hexarelin is a stronger GH-releasing peptide than GHRH in normal cycling women but not in anorexia nervosa. ([`pubmed-observation-pmid-9258804-2026-10-12-93dde64fe596`](#source-pubmed-observation-pmid-9258804-2026-10-12-93dde64fe596))

#### Summary

PubMed lists PMID 9258804 in Journal of endocrinological investigation as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1997-05 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9258804-2026-10-12-93dde64fe596`](#source-pubmed-observation-pmid-9258804-2026-10-12-93dde64fe596))

#### Paragraph 1

PubMed lists PMID 9258804 in Journal of endocrinological investigation as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1997-05 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9258804-2026-10-12-93dde64fe596`](#source-pubmed-observation-pmid-9258804-2026-10-12-93dde64fe596))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-9258804-2026-10-12-93dde64fe596`](#source-pubmed-observation-pmid-9258804-2026-10-12-93dde64fe596))

### Sources

<a id="source-pubmed-observation-pmid-9258804-2026-10-12-93dde64fe596"></a>
- **Hexarelin is a stronger GH-releasing peptide than GHRH in normal cycling women but not in anorexia nervosa. · retained source version 1:2026-10-12:current:93dde64fe596df826ba23a94c3904d43649f10e0819ae6d14c314371e885f97c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/9258804/) (`pubmed-observation-pmid-9258804-2026-10-12-93dde64fe596`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Hexarelin is a stronger GH-releasing peptide than GHRH in normal cycling women but not in anorexia nervosa." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-9258804-hexarelin-v1 SHA-256: 3d7207227bef3a120288543cf808c696132ee37d0c23167b18752d4c1d568df8.

---

<a id="pubmed-pmid-9279881-hexarelin-v1"></a>

## Hepatic extraction of hexarelin, a new peptidic GH secretagogue, in the isolated perfused rat liver.

> PubMed lists PMID 9279881 in Pharmaceutical research as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1997-08 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-9279881-hexarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-19
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-9279881-hexarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-9279881-hexarelin-v1
- Content SHA-256: `dd215c1ba10fbc73d2a82da558951573d8e6a418e34faf5f624d901cf57811da`

### Claims and source pins

#### Headline

Hepatic extraction of hexarelin, a new peptidic GH secretagogue, in the isolated perfused rat liver. ([`pubmed-observation-pmid-9279881-2026-10-19-1be43273e2b0`](#source-pubmed-observation-pmid-9279881-2026-10-19-1be43273e2b0))

#### Summary

PubMed lists PMID 9279881 in Pharmaceutical research as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1997-08 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9279881-2026-10-19-1be43273e2b0`](#source-pubmed-observation-pmid-9279881-2026-10-19-1be43273e2b0))

#### Paragraph 1

PubMed lists PMID 9279881 in Pharmaceutical research as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1997-08 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9279881-2026-10-19-1be43273e2b0`](#source-pubmed-observation-pmid-9279881-2026-10-19-1be43273e2b0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-9279881-2026-10-19-1be43273e2b0`](#source-pubmed-observation-pmid-9279881-2026-10-19-1be43273e2b0))

### Sources

<a id="source-pubmed-observation-pmid-9279881-2026-10-19-1be43273e2b0"></a>
- **Hepatic extraction of hexarelin, a new peptidic GH secretagogue, in the isolated perfused rat liver. · retained source version 1:2026-10-19:current:1be43273e2b0b80cd12f9f41f7ca5601559c0a0761e1ec45e8d01bc017030796** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/9279881/) (`pubmed-observation-pmid-9279881-2026-10-19-1be43273e2b0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Hepatic extraction of hexarelin, a new peptidic GH secretagogue, in the isolated perfused rat liver." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-9279881-hexarelin-v1 SHA-256: dd215c1ba10fbc73d2a82da558951573d8e6a418e34faf5f624d901cf57811da.

---

<a id="pubmed-pmid-9425393-hexarelin-v1"></a>

## Interaction of the growth hormone releasing peptide hexarelin with somatostatin.

> PubMed lists PMID 9425393 in Clinical endocrinology as Clinical Trial, Controlled Clinical Trial, Journal Article, with publication-date metadata of 1997-11 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-9425393-hexarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-08-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-9425393-hexarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-9425393-hexarelin-v1
- Content SHA-256: `b4828f1115e02d93f2aef0c62397e74b2ebaa053e62be54be8a43a3b925a70dd`

### Claims and source pins

#### Headline

Interaction of the growth hormone releasing peptide hexarelin with somatostatin. ([`pubmed-observation-pmid-9425393-2019-08-13-52314b462f32`](#source-pubmed-observation-pmid-9425393-2019-08-13-52314b462f32))

#### Summary

PubMed lists PMID 9425393 in Clinical endocrinology as Clinical Trial, Controlled Clinical Trial, Journal Article, with publication-date metadata of 1997-11 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9425393-2019-08-13-52314b462f32`](#source-pubmed-observation-pmid-9425393-2019-08-13-52314b462f32))

#### Paragraph 1

PubMed lists PMID 9425393 in Clinical endocrinology as Clinical Trial, Controlled Clinical Trial, Journal Article, with publication-date metadata of 1997-11 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9425393-2019-08-13-52314b462f32`](#source-pubmed-observation-pmid-9425393-2019-08-13-52314b462f32))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-9425393-2019-08-13-52314b462f32`](#source-pubmed-observation-pmid-9425393-2019-08-13-52314b462f32))

### Sources

<a id="source-pubmed-observation-pmid-9425393-2019-08-13-52314b462f32"></a>
- **Interaction of the growth hormone releasing peptide hexarelin with somatostatin. · retained source version 1:2019-08-13:current:52314b462f32815ffb87cdeb925a5c194c4d473ba512d29156b26dd67b09d973** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/9425393/) (`pubmed-observation-pmid-9425393-2019-08-13-52314b462f32`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Interaction of the growth hormone releasing peptide hexarelin with somatostatin." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-9425393-hexarelin-v1 SHA-256: b4828f1115e02d93f2aef0c62397e74b2ebaa053e62be54be8a43a3b925a70dd.

---

<a id="pubmed-pmid-9534309-hexarelin-v1"></a>

## Hexarelin, a growth hormone-releasing peptide, discloses protectant activity against cardiovascular damage in rats with isolated growth hormone deficiency.

> PubMed lists PMID 9534309 in Cardiologia (Rome, Italy) as Journal Article, with publication-date metadata of 1997-11 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-9534309-hexarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2012-11-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-9534309-hexarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-9534309-hexarelin-v1
- Content SHA-256: `beb43116f8b269508ea8348370f0a4f2010f010fb4571ce6fc0cc51f44191d00`

### Claims and source pins

#### Headline

Hexarelin, a growth hormone-releasing peptide, discloses protectant activity against cardiovascular damage in rats with isolated growth hormone deficiency. ([`pubmed-observation-pmid-9534309-2012-11-15-d54ae81873b7`](#source-pubmed-observation-pmid-9534309-2012-11-15-d54ae81873b7))

#### Summary

PubMed lists PMID 9534309 in Cardiologia (Rome, Italy) as Journal Article, with publication-date metadata of 1997-11 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9534309-2012-11-15-d54ae81873b7`](#source-pubmed-observation-pmid-9534309-2012-11-15-d54ae81873b7))

#### Paragraph 1

PubMed lists PMID 9534309 in Cardiologia (Rome, Italy) as Journal Article, with publication-date metadata of 1997-11 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9534309-2012-11-15-d54ae81873b7`](#source-pubmed-observation-pmid-9534309-2012-11-15-d54ae81873b7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-9534309-2012-11-15-d54ae81873b7`](#source-pubmed-observation-pmid-9534309-2012-11-15-d54ae81873b7))

### Sources

<a id="source-pubmed-observation-pmid-9534309-2012-11-15-d54ae81873b7"></a>
- **Hexarelin, a growth hormone-releasing peptide, discloses protectant activity against cardiovascular damage in rats with isolated growth hormone deficiency. · retained source version 1:2012-11-15:current:d54ae81873b7654eafdf1041266395cd668880e5e2f73bc1dbd550685122a7ee** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/9534309/) (`pubmed-observation-pmid-9534309-2012-11-15-d54ae81873b7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Hexarelin, a growth hormone-releasing peptide, discloses protectant activity against cardiovascular damage in rats with isolated growth hormone deficiency." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-9534309-hexarelin-v1 SHA-256: beb43116f8b269508ea8348370f0a4f2010f010fb4571ce6fc0cc51f44191d00.

---

<a id="pubmed-pmid-9589671-hexarelin-v1"></a>

## Growth hormone status during long-term hexarelin therapy.

> PubMed lists PMID 9589671 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1998-05 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-9589671-hexarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2012-11-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-9589671-hexarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-9589671-hexarelin-v1
- Content SHA-256: `67e60c929fda880bfb7a8569559c77027825e30ce78ca1c32617a93f88276614`

### Claims and source pins

#### Headline

Growth hormone status during long-term hexarelin therapy. ([`pubmed-observation-pmid-9589671-2012-11-15-496b4fae4d51`](#source-pubmed-observation-pmid-9589671-2012-11-15-496b4fae4d51))

#### Summary

PubMed lists PMID 9589671 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1998-05 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9589671-2012-11-15-496b4fae4d51`](#source-pubmed-observation-pmid-9589671-2012-11-15-496b4fae4d51))

#### Paragraph 1

PubMed lists PMID 9589671 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1998-05 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9589671-2012-11-15-496b4fae4d51`](#source-pubmed-observation-pmid-9589671-2012-11-15-496b4fae4d51))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-9589671-2012-11-15-496b4fae4d51`](#source-pubmed-observation-pmid-9589671-2012-11-15-496b4fae4d51))

### Sources

<a id="source-pubmed-observation-pmid-9589671-2012-11-15-496b4fae4d51"></a>
- **Growth hormone status during long-term hexarelin therapy. · retained source version 1:2012-11-15:current:496b4fae4d51d1d522b6b79616e2df4b4bcfee891bd749ef8aedfe63b098c464** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/9589671/) (`pubmed-observation-pmid-9589671-2012-11-15-496b4fae4d51`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Growth hormone status during long-term hexarelin therapy." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-9589671-hexarelin-v1 SHA-256: 67e60c929fda880bfb7a8569559c77027825e30ce78ca1c32617a93f88276614.

---

<a id="pubmed-pmid-9694949-hexarelin-v1"></a>

## Partial recovery of skeletal muscle sodium channel properties in aged rats chronically treated with growth hormone or the GH-secretagogue hexarelin.

> PubMed lists PMID 9694949 in The Journal of pharmacology and experimental therapeutics as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1998-08 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-9694949-hexarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2012-11-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-9694949-hexarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-9694949-hexarelin-v1
- Content SHA-256: `ec0bbc1f7a005f6132842ab43c1ce316b90c061e7b76c46aaaab8edba6c59392`

### Claims and source pins

#### Headline

Partial recovery of skeletal muscle sodium channel properties in aged rats chronically treated with growth hormone or the GH-secretagogue hexarelin. ([`pubmed-observation-pmid-9694949-2012-11-15-1b5b835afa87`](#source-pubmed-observation-pmid-9694949-2012-11-15-1b5b835afa87))

#### Summary

PubMed lists PMID 9694949 in The Journal of pharmacology and experimental therapeutics as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1998-08 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9694949-2012-11-15-1b5b835afa87`](#source-pubmed-observation-pmid-9694949-2012-11-15-1b5b835afa87))

#### Paragraph 1

PubMed lists PMID 9694949 in The Journal of pharmacology and experimental therapeutics as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1998-08 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9694949-2012-11-15-1b5b835afa87`](#source-pubmed-observation-pmid-9694949-2012-11-15-1b5b835afa87))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-9694949-2012-11-15-1b5b835afa87`](#source-pubmed-observation-pmid-9694949-2012-11-15-1b5b835afa87))

### Sources

<a id="source-pubmed-observation-pmid-9694949-2012-11-15-1b5b835afa87"></a>
- **Partial recovery of skeletal muscle sodium channel properties in aged rats chronically treated with growth hormone or the GH-secretagogue hexarelin. · retained source version 1:2012-11-15:current:1b5b835afa8799698421f0ca17ee39d89704e0645c3277bb58eddfec5b43a507** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/9694949/) (`pubmed-observation-pmid-9694949-2012-11-15-1b5b835afa87`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Partial recovery of skeletal muscle sodium channel properties in aged rats chronically treated with growth hormone or the GH-secretagogue hexarelin." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-9694949-hexarelin-v1 SHA-256: ec0bbc1f7a005f6132842ab43c1ce316b90c061e7b76c46aaaab8edba6c59392.

---

<a id="pubmed-pmid-9700988-hexarelin-v1"></a>

## Protectant activity of hexarelin or growth hormone against postischemic ventricular dysfunction in hearts from aged rats.

> PubMed lists PMID 9700988 in Journal of cardiovascular pharmacology as Journal Article, with publication-date metadata of 1998-08 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-9700988-hexarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-07-24
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-9700988-hexarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-9700988-hexarelin-v1
- Content SHA-256: `73ba353b98201051c8dde2bced6eb8fbc0cbb82db828730331560c6d009b7400`

### Claims and source pins

#### Headline

Protectant activity of hexarelin or growth hormone against postischemic ventricular dysfunction in hearts from aged rats. ([`pubmed-observation-pmid-9700988-2019-07-24-a636b9eafc5f`](#source-pubmed-observation-pmid-9700988-2019-07-24-a636b9eafc5f))

#### Summary

PubMed lists PMID 9700988 in Journal of cardiovascular pharmacology as Journal Article, with publication-date metadata of 1998-08 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9700988-2019-07-24-a636b9eafc5f`](#source-pubmed-observation-pmid-9700988-2019-07-24-a636b9eafc5f))

#### Paragraph 1

PubMed lists PMID 9700988 in Journal of cardiovascular pharmacology as Journal Article, with publication-date metadata of 1998-08 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9700988-2019-07-24-a636b9eafc5f`](#source-pubmed-observation-pmid-9700988-2019-07-24-a636b9eafc5f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-9700988-2019-07-24-a636b9eafc5f`](#source-pubmed-observation-pmid-9700988-2019-07-24-a636b9eafc5f))

### Sources

<a id="source-pubmed-observation-pmid-9700988-2019-07-24-a636b9eafc5f"></a>
- **Protectant activity of hexarelin or growth hormone against postischemic ventricular dysfunction in hearts from aged rats. · retained source version 1:2019-07-24:current:a636b9eafc5fadaa7816df0223dc84e52ea6d46dd7722a061ecb50cdf09b6c41** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/9700988/) (`pubmed-observation-pmid-9700988-2019-07-24-a636b9eafc5f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Protectant activity of hexarelin or growth hormone against postischemic ventricular dysfunction in hearts from aged rats." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-9700988-hexarelin-v1 SHA-256: 73ba353b98201051c8dde2bced6eb8fbc0cbb82db828730331560c6d009b7400.

---

<a id="pubmed-pmid-9801989-hexarelin-v1"></a>

## Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects.

> PubMed lists PMID 9801989 in Journal of endocrinological investigation as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1998-09 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-9801989-hexarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-03-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-9801989-hexarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-9801989-hexarelin-v1
- Content SHA-256: `0f21b0c8a6a4e3bc2d032b74f39124dbc80fc6b8551fb880e60dac2552b7091c`

### Claims and source pins

#### Headline

Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects. ([`pubmed-observation-pmid-9801989-2022-03-09-4618174a899e`](#source-pubmed-observation-pmid-9801989-2022-03-09-4618174a899e))

#### Summary

PubMed lists PMID 9801989 in Journal of endocrinological investigation as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1998-09 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9801989-2022-03-09-4618174a899e`](#source-pubmed-observation-pmid-9801989-2022-03-09-4618174a899e))

#### Paragraph 1

PubMed lists PMID 9801989 in Journal of endocrinological investigation as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1998-09 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9801989-2022-03-09-4618174a899e`](#source-pubmed-observation-pmid-9801989-2022-03-09-4618174a899e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-9801989-2022-03-09-4618174a899e`](#source-pubmed-observation-pmid-9801989-2022-03-09-4618174a899e))

### Sources

<a id="source-pubmed-observation-pmid-9801989-2022-03-09-4618174a899e"></a>
- **Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects. · retained source version 1:2022-03-09:current:4618174a899e114e20b9d79038c1f62df7e13b4b303da0f7096d2bea40363aba** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/9801989/) (`pubmed-observation-pmid-9801989-2022-03-09-4618174a899e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-9801989-hexarelin-v1 SHA-256: 0f21b0c8a6a4e3bc2d032b74f39124dbc80fc6b8551fb880e60dac2552b7091c.

---

<a id="pubmed-pmid-9851753-hexarelin-v1"></a>

## Adrenocorticotropin and cortisol hyperresponsiveness to hexarelin in patients with Cushing's disease bearing a pituitary microadenoma, but not in those with macroadenoma.

> PubMed lists PMID 9851753 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1998-12 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-9851753-hexarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-9851753-hexarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-9851753-hexarelin-v1
- Content SHA-256: `d577715c9ad287e5d4a156508f45bbb173a33b666288fe52e94cb091339543bd`

### Claims and source pins

#### Headline

Adrenocorticotropin and cortisol hyperresponsiveness to hexarelin in patients with Cushing's disease bearing a pituitary microadenoma, but not in those with macroadenoma. ([`pubmed-observation-pmid-9851753-2018-12-01-4d52bea60655`](#source-pubmed-observation-pmid-9851753-2018-12-01-4d52bea60655))

#### Summary

PubMed lists PMID 9851753 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1998-12 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9851753-2018-12-01-4d52bea60655`](#source-pubmed-observation-pmid-9851753-2018-12-01-4d52bea60655))

#### Paragraph 1

PubMed lists PMID 9851753 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1998-12 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9851753-2018-12-01-4d52bea60655`](#source-pubmed-observation-pmid-9851753-2018-12-01-4d52bea60655))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-9851753-2018-12-01-4d52bea60655`](#source-pubmed-observation-pmid-9851753-2018-12-01-4d52bea60655))

### Sources

<a id="source-pubmed-observation-pmid-9851753-2018-12-01-4d52bea60655"></a>
- **Adrenocorticotropin and cortisol hyperresponsiveness to hexarelin in patients with Cushing's disease bearing a pituitary microadenoma, but not in those with macroadenoma. · retained source version 1:2018-12-01:current:4d52bea60655cb92ea0aab368e3f255cbaebc153010f94b2eccb94412f45e39f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/9851753/) (`pubmed-observation-pmid-9851753-2018-12-01-4d52bea60655`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Adrenocorticotropin and cortisol hyperresponsiveness to hexarelin in patients with Cushing's disease bearing a pituitary microadenoma, but not in those with macroadenoma." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/hexarelin.json#pubmed-pmid-9851753-hexarelin-v1 SHA-256: d577715c9ad287e5d4a156508f45bbb173a33b666288fe52e94cb091339543bd.

